Gagnon and colleagues (2024) demonstrated that the inhibition of ANGPTL4 reduced the risk of CAD and diabetes, demonstrating that ANGPTL4 inhibition may represent an effective target for the prevention or treatment of cardiometabolic diseases [40]. The gene discussed is ANGPTL4; the disease is diabetes mellitus.